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Most forms of chemotherapy employ mechanisms
involving induction of oxidative stress, a strategy
that can be effective due to the elevated oxidative
state commonly observed in cancer cells. However,
recent studies have shown that relative redox levels
in primary tumors can be heterogeneous, suggesting
that regimens dependent on differential oxidative
state may not be uniformly effective. To investigate
this issue in hematological malignancies, we evalu-
ated mechanisms controlling oxidative state in
primary specimens derived from acute myelogenous
leukemia (AML) patients. Our studies demonstrate
three striking findings. First, the majority of function-
ally defined leukemia stem cells (LSCs) are charac-
terized by relatively low levels of reactive oxygen
species (termed ‘‘ROS-low’’). Second, ROS-low
LSCs aberrantly overexpress BCL-2. Third, BCL-2
inhibition reduced oxidative phosphorylation and
selectively eradicated quiescent LSCs. Based on
these findings, we propose a model wherein the
unique physiology of ROS-low LSCs provides an
opportunity for selective targeting via disruption of
BCL-2-dependent oxidative phosphorylation.
INTRODUCTION
Biological analyses of leukemia stem cells (LSCs) has been the
focus of numerous studies over the past decade, with reports
describing molecular, cellular, biochemical, and genetic proper-
ties in both human and mouse systems. It has been assumed to
at least some extent that the biology of LSCs mirrors that of
normal tissues, where malignant stem cells reside at the apex
of a hierarchical developmental structure. Indeed, key stem
cell properties such as self-renewal are readily evident in stem
cells from multiple tumor types (Magee et al., 2012). In addition,
quiescent cell cycle status, a very well described feature ofCnormal hematopoietic stem cells (HSCs), also appears to be
a central property of functionally defined acute myeloid leukemia
(AML) stem cells (Saito et al., 2010). Further, several molecular
mechanisms that regulate normal stem cell properties are also
frequently active (and/or aberrant) in cancer cell types as well
(Magee et al., 2012). These observations have led investigators
to attempt targeting of LSC populations based on properties
that are thought to be shared among normal and tumor primitive
cells and are conserved from patient to patient.
Despite the similarities noted above, it has become increas-
ingly clear that primitive cancer cell types possess important
differences from normal tissues, some of which run counter to
conventional views of stem cell biology. For example, recent
studies have shown that cell surface immunophenotype can
vary widely among specimens derived from primary AML
patients, and that commonly used stem cell antigens such as
CD34 and CD38 do not show consistent levels of expression
on LSCs (Eppert et al., 2011; Sarry et al., 2011). Thus, unlike
normal hematopoietic tissues, which show substantial interspe-
cimen similarities, some of the biological properties of indepen-
dent LSCs may be highly disparate and/or unstable.
Given the observations outlined above, we sought to better
define fundamental aspects of LSC biology, which are con-
served irrespective of interpatient or intrapatient heterogeneity.
To this end, we investigated energy metabolism, a basic require-
ment of any cell type. Cancer cells appear to commonly acquire
aberrancies in energy metabolism and cellular redox state
(Cairns et al., 2011). In contrast to their normal counterparts,
cancer cells tend in the presence of oxygen to employ glycolysis
instead of aerobic mitochondrial respiration to generate energy
(Warburg, 1956). Notably, in at least some instances, cancer
cells generate increased levels of reactive oxygen species
(ROS) (Trachootham et al., 2008). This notion has provided the
impetus to explore redox modulation as a therapeutic target
in cancer, with the rationale that pro-oxidants may eradicate
tumor cells by pushing them beyond the limits of viability (Tra-
chootham et al., 2009). However, while such tumor-related
metabolic adaptations characterize bulk tumor tissues, it is
unclear whether cancer stem cells (CSCs) also exhibit an
increased oxidative state. Indeed, previous studies by Diehn
et al. (2009) demonstrated that breast cancer cells enrichedell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc. 329
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showed lower levels of ROS than the ‘‘non CD24/CD44+’’ cells.
Gaining further insights into the metabolic properties of CSCs
may reveal physiological dependencies that can be targeted
for therapy.
In the present study we used primary human AML specimens
and a stringent xenograft assay to investigate the oxidative state
and the bioenergetic properties of LSCs. We show that in
contrast to the nontumorigenic cells, the majority of self-renew-
ing and chemotherapy-resistant primitive leukemic populations
are quiescent tumor subsets characterized by a low rate of
energy metabolism and a low cellular oxidative status (termed
‘‘ROS-low’’). Surprisingly, ROS-low cells are unable to utilize
glycolysis when mitochondrial respiration is inhibited. Thus, we
show that the maintenance of mitochondrial function is essen-
tial for LSC survival. Finally, we demonstrate a unique role for
BCL-2 in ROS-low cell mitochondrial respiration, and show
that small molecule BCL-2 inhibitors can effectively target
chemotherapy-resistant LSCs by impairing their energy genera-
tion capacity and redox control. Our findings indicate it is fea-
sible to eradicate therapy-resistant LSC populations by targeting
their unique metabolic dependencies.
RESULTS
Stem Cell Properties of Primary AML Populations
Isolated on the Basis of Intracellular ROS
To characterize leukemia cells with differing oxidative state, we
employed a method previously reported by Jang and Sharkis
(2007). In this study, the authors used cell sorting based on the
relative fluorescence of redox-sensitive probes to isolate HSCs
with differing endogenous ROS levels. Since a number of recent
studies have highlighted that LSCs may display disparate
phenotypic patterns besides CD34+/CD38/CD123+ (Eppert
et al., 2011; Sarry et al., 2011), in performing our initial analyses
of ROS levels in primary AML samples, we did not rely on
standard phenotypic profiles, but rather examined the entire
leukemic population. By employing several redox-sensitive
probes commonly used to measure intracellular ROS (CM-
H2DCFDA, CellROX,MitoSox, Mitotracker, and DHE) we consis-
tently observed substantial heterogeneity in the redox staining
profile of AML specimens (Figure 1A and Figures S1A and S1B
available online). Since the fluorescent dyes CM-H2DCFDA
and CellROX provide a broader measure of intracellular redox
levels, we used those two dyes to sort AML specimens into
subsets with low and high endogenous ROS (defined as the
15% dimmest and brightest dye fluorescence distribution as
shown in Figure 1A) and then analyzed the two populations for
stem cell properties.
A critical feature of both normal and leukemia primitive popu-
lations is quiescence, as increased proliferation can lead to
exhaustion of stem cell function (Ito et al., 2006; Tothova et al.,
2007). We hypothesized that quiescence may reduce LSCmeta-
bolic activity and thus lower ROS production, so slowly prolifer-
ating LSCs should be enriched in the redox low compartment. To
investigate this issue, we colabeled sorted ROS-low and ROS-
high fractions with anti-Ki67 and 7AAD to evaluate cell cycle
status. As shown in Figures 1B and 1C, leukemic ROS-low cells
are preferentially enriched for G0 quiescent cells. This finding330 Cell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc.was corroborated by analyses of cell cycle components, which
demonstrated reduced expression of CDK1; cyclins A2, B2, D3
and E2; and increased expression of the cell cycle inhibitor
p27 in ROS-low cells (Figures S1C and S1D). ROS-low cells
also showed reduced expression of the MAPK kinase phos-
pho-p38, which is associated with redox state regulation and
cell cycle activity in normal hematopoiesis (Figure S1D) (Ito
et al., 2006). Interestingly, ROS-low subsets isolated from the
M9-ENL1 AML cell line and from normal marrow CD34+ cells
were also more quiescent as compared to corresponding
ROS-high cells (Figure S1E), indicating that the association
between lower ROS and quiescence is conserved in both cell
lines and normal HSCs.
To assess whether AML cells with lower endogenous ROS are
enriched for primitive leukemia cells, we first performed in vitro
colony assays to determine colony-forming units (CFUs). In
four evaluable AML samples, the leukemic cells with lower
ROS gave growth to more CFUs in comparison to ROS-high or
total AML cells (Figure 1D), suggesting enrichment of primitive
cells in the ROS-low compartment. To functionally evaluate
LSC potential, xenograft studies were performed using trans-
plantation of primary human cells into immune deficient NOD/
SCID-IL2Rg/ (NSG) mice. As shown in Figure 1E, LSC activity
(i.e., successful engraftment of NSGmice) is readily evident in all
ROS-low AML subsets evaluated (five of five independent spec-
imens). Notably, in two of five specimens we also detected some
LSCactivity (albeit at lower levels) with ROS-high AML cells, sug-
gesting that functionally defined primitive leukemia populations
can exist across a relatively broad ROS gradient in at least
some cases. However, the leukemic subsets isolated from the
lowest end of the ROS range were consistently more enriched
for LSC activity as compared to AML cells containing high levels
of ROS (Figure 1E and Figure S1F). Indeed, in transplantation
experiments (Figure 1E), despite the fact that AML ROS-low cells
were injected in NSG mice at a 5-fold lower dose than unfractio-
nated total AML cells (Table S2), the ROS-low population
engrafted at levels comparable to the total AML cells (AML
ROS-low = 44.6 ± 38 versus total AML = 51 ± 38, p = 0.122 >
0.05, n = 5). Further, to address whether ROS-low cells fulfill
the stem cell criterion of long-term self-renewal, we performed
serial transplantation studies in secondary mouse recipients.
ROS-low leukemic cells reestablished AML in the secondary
recipients in all cases, thus confirming their leukemic stem cell
potential (Table S3). Interestingly, in two out of three AML spec-
imens where ROS-high AML cells engrafted at levels that
allowed comparative serial transplantation analyses, we ob-
served long-term self-renewal potential in secondary recipients,
suggesting that LSCs are significantly fewer but evident within
the redox high leukemic compartment (Table S3). Since normal
HSCs have been suggested to reside in a reduced oxidized
state, we next tested if the increased engraftment potential of
the ROS-low AML subset resulted from contributing HSCs (To-
thova et al., 2007). To this end we analyzed the human cells
from mice engrafted with ROS-low or ROS-high AML cells
(patient sample #1) for expression of mutant nucleophosmin
(NPM), which is a frequently observed leukemia marker (Falini
et al., 2007). Engrafted AML cells from both leukemic subsets
were positive for this marker (Figure S1G), thus confirming the
leukemic origin of engrafted cells in both cases.
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Figure 1. Stem Cell Properties of Leukemia Cells Isolated on the Basis of Intracellular ROS
(A) CM-H2DCFDA labeling of primary AML specimen. DCF; CM-H2DCFDA. See also Figures S1A and S1B.
(B) Representative cell cycle analysis of sorted ROS-low and ROS-high primary AML subsets performed by Ki67 and 7AAD labeling.
(C) Cell cycle analyses from n = 9 primary AML samples are summarized. Mean ± SEM percentages of G0 cells are plotted. See also Figures S1C–S1E.
(D) Number of colonies per 53 104 cultured cells in total AML, ROS-low, and ROS-high subsets. Mean ± SEM values of n = 4 primary AML specimens are plotted.
(E) Total AML, ROS-low, and ROS-high leukemia subsets were transplanted into NSG mice at a constant cell ratio of 5:1:1 as described in the Experimental
Procedures. Mice were killed 6–8 weeks later, and their marrow was analyzed by flow cytometry for engraftment of human leukemia cells. Results from n = 5
independent AML specimens are shown. See also Figure S1F.
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Energy Metabolism in Leukemia Stem CellsWe next asked if AML cells containing lower levels of ROS
are enriched for the CD34+/CD38 phenotypic profile, which is
commonly associated with stem cells in both normal and
leukemic hematopoiesis. We found an increased percentage of
CD34+/CD38 cells in the ROS-low subset as compared to
those in the ROS-high, but no significant enrichment of this
phenotypic profile when the ROS-low cells where compared to
the total AML population (Figure S1H). Further, analysis of AML
specimens with an additional collection of antibodies associated
with primitive cell types (CD123, CD33, CD117, CD90, and
CD44) did not reveal any clear association between surface
expression profile and a lower oxidative state (data not shown).
Taken together, these findings indicate that endogenous ROS
levels can be used as a tool to prospectively isolate LSC-en-
riched populations. To identify properties of LSCs that can be
targeted for therapy, we therefore used endogenous ROS sort-Cing to enrich for LSCs, and studied mechanisms controlling
energy metabolism in LSC-enriched populations.
LSC-Enriched Primary Populations Are Metabolically
Dormant and Are Dependent on Oxidative Respiration
rather than Glycolysis for Energy Generation
To gain insights into the metabolic regulation of LSCs, we
performed bioenergetic analyses in ROS-low and ROS-high
primary AML specimens. We first investigated the relative
dependence of the ROS-low AML cells to the two major
energy-generating pathways: mitochondrial oxidative phos-
phorylation (OXPHOS) and glycolysis. To this end, we used
the Seahorse XF24 extracellular flux analyzer to measure the
oxygen consumption rate (OCR) indicative of OXPHOS, and
the lactate production indicative of glycolysis (extracellular
acidification rate; ECAR). As shown in Figure 2A, LSC-enrichedell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc. 331
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Figure 2. Bioenergetic Analyses in LSC-Enriched versus Bulk Leukemic and Normal Primitive Populations
(A) Basal oxygen consumption rate (OCR) in total AML and ROS-low cells versus ROS-high subsets, as evaluated by the Seahorse XF24 extracellular flux
analyzer. Five replicate wells of 53 105 ROS-low and ROS-high leukemic cells were analyzed. Mean ± SEM values from n = 5 AML specimens are plotted. *p%
0.05. See also Figure S2.
(B) Protein expression levels of the NADPH oxidase subunit NOX2 (gp91phox) in ROS-low versus ROS-high primary subsets, as evaluated by flow cytometry.
Mean fluorescence intensity values are plotted. AU, arbitrary units.
(C) Mean ± SEM values of baseline extracellular acidification rate (ECAR) indicative of glycolytic rate in n = 5 primary AML specimens. *p% 0.05.
(D) Reserved glycolytic capacity in ROS-low cells (red) versus ROS-high AML cells (black) in a primary AML specimen. ECAR was measured without (first two
measurements) and in the presence of (measurements 3–8) the mitochondrial inhibitors oligomycin (OLI, 1 mg/ml), FCCP (1 mM), and Antimycin (AA, 5 mM). Basal
ECAR is calculated as the mean of measurements 1 and 2. Reserved glycolytic capacity is determined as themean of the measurements 5 and 6minus the mean
of the first two measurements.
(E) Mean ± SEM values of reserved glycolytic capacity in n = 5 primary AML specimens. *p% 0.05.
(F) Mean values of baseline ATP levels in ROS-low versus ROS-high leukemia cells.
(G) Representative experiment of reserved glycolytic capacity in normal CD34+ (red) versus CD34 (black) marrow cells.
(H) Plot of mean ± SEM values of reserved glycolytic capacity from two independent experiments in CD34+ versus CD34 normal subsets. Reserved glycolytic
capacity was determined as in (D). *p% 0.05.
(I) Basal oxygen consumption rate (OCR) of normal marrow CD34+ versus CD34 subsets. Mean ± SEM values are plotted.
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Energy Metabolism in Leukemia Stem CellsROS-low cells showed a significantly lower OCR rate, indicative
of lower oxidative metabolism, as compared to the total and
ROS-high AML cells. While oxidative processes occur mainly
in mitochondria, oxidative activity can also be found in the cyto-
plasmic membrane due to the presence of the NADPH oxidases
(Hole et al., 2010). Therefore, we evaluated the protein expres-
sion of NADPH oxidase subunit NOX2 (gp91phox) by flow
cytometry. As shown in Figure 2B, NOX2 levels were found to
be quite low in ROS-low cells, indicating mitochondria as the
primary site of oxidative metabolism in LSC-enriched popula-
tions. AML ROS-low cells isolated based on the fluorescence
of the redox dye CM-H2DCFDA also showed reduced labeling
with the mitochondrial-specific redox probe MitoSox-Red, indi-
cating a lower content of mitochondrial-derived ROS (Figure S2).
We next examined relative rates of glycolysis and observed that
ROS-low cells are substantially less active with respect to this
anaerobic form of energy production as well (Figure 2C). While
the basal rate of glycolysis in ROS-low cells is low, it is possible
that under certain conditions (i.e., in hypoxic niches in vivo) LSCs
might compensate for low OXPHOS by upregulating glycolysis.
To investigate this issue we measured lactate generation indica-
tive of the cellular glycolytic rate after treatment of cells with the
mitochondrial respiration inhibitors oligomycin (OLI) and FCCP.
OLI and FCCP inhibit mitochondrial respiration and force cells
to the glycolytic pathway to maintain energy supply, so treat-
ment with these agents is indicative of the reserved cellular
glycolytic potential. Surprisingly, LSC-enriched ROS-low AML
cells showed a significantly decreased potential to upregulate
the glycolytic machinery and thus sustain energy generation
when mitochondrial energy production was inhibited (Figures
2D and 2E). In agreement with our bioenergetic data, ROS-low
cells showed significantly decreased ATP levels in all samples
evaluated (Figure 2F).
To determine whether the metabolic status of ROS-low
AML cells represents an aberrant condition, we performed com-
parative bioenergetic analyses of normal bone marrow CD34+
progenitors isolated from healthy volunteers. A recent study
showed that murine hematopoietic stem populations are pre-
dominantly glycolytic (Simsek et al., 2010), but to our knowledge
the bioenergetic profile of human marrow progenitors has not
been previously investigated. We found that, in contrast to
AML ROS-low cells, normal CD34+ cells are metabolically active
cells with baseline glycolysis and OXPHOS rates similar to
CD34 cells (Figures 2G and 2I). Further, normal CD34+ progen-
itors preferentially (in comparison with CD34 cells) upregulate
glycolysis when mitochondrial OXPHOS is blocked (Figures
2G and 2H).
Taken together, our metabolic analyses indicate that LSC-en-
riched subsets aremetabolically dormant tumor populations that
reside in a substantially decreased energetic state. Importantly,
our findings further suggest that in contrast to normal progenitor
cells, LSC-enriched subsets may paradoxically depend more on
mitochondrial respiration rather than glycolysis to meet their
energy demands and maintain their survival.
BCL-2 Is Upregulated in LSC-Enriched Primary AML
Populations
To investigate mechanisms that control oxidative state and
metabolic processes in ROS-low and ROS-high populations,Cwe performed gene expression studies using RNA-seq-based
methods. Since our findings indicated LSC-enriched popula-
tions contained lower levels of ROS, we investigated if upregu-
lation of antioxidant genes represents a prominent feature of
ROS-low AML cells. We found only a small number of genes
related to antioxidant defenses to be significantly altered in
ROS-low AML cells, none of which were consistently upregu-
lated in the ROS-low population (Figure S3A). We next investi-
gated the relative expression of genes related to mitochondria
and energy metabolism. In agreement with an important role
of mitochondrial metabolism in LSCs, we found several mito-
chondrial-related genes upregulated in ROS-low cells. These
included the SLC25A42 and SLC25A38 mitochondrial carriers
that transport metabolites and amino acids across the mito-
chondrial membrane, and the gene FIS1, which is critical for
mitochondrial dynamics and fission (Figure 3A) (Westermann,
2010). Intriguingly, we found that the LSC-enriched ROS-low
population expressed significantly higher levels of BCL-2 (Fig-
ure 3A). We validated this initial observation using quantitative
PCR in a larger AML sample cohort (Figure 3B). BCL-2 mRNA
expression correlated with protein expression, as ROS-low
AML cells expressed higher levels of BCL-2 protein (Figure 3C),
whereas they showed no significant upregulation of other antia-
poptotic BCL-2 family members including BCL-XL and MCL-1
(Figures S3B and S3C). Parallel analyses of BCL-2 gene expres-
sion in normal marrow specimens showed, in agreement with
previous observations (Delia et al., 1992), that normal CD34+
progenitors express significantly higher levels of BCL-2 as
compared to more differentiated CD34 cells (Figures S3D–
S3F). To investigate the extent to which normal CD34+ progeni-
tors share the BCL-2 expression profile observed in leukemic
cells, we further examined BCL-2 levels in normal CD34+ ROS-
low versus ROS-high populations. To this end, we enriched for
CD34+ progenitors using an immunomagnetic affinity column
and then isolated CD34+ ROS-low and ROS-high populations
by flow cytometry. CD34+ ROS-low cells showed a modest
increase in BCL-2 mRNA expression as compared to CD34+
ROS-high, but we found no difference in the BCL-2 protein levels
among the two populations in three independent experiments
(Figures S3G–S3H). Based on these data, we conclude there is
no differential activity of BCL-2 between normal ROS-low and
ROS-high compartments.
The upregulation of BCL-2 in the LSC is potentially important,
since (1) BCL-2 has an established role as an inhibitor of
the mitochondrial-initiated proapoptotic pathway and thus can
represent an important contributor in the chemoresistance prop-
erties of LSCs (Del Poeta et al., 2003), and (2) recent evidence
points to a noncanonical activity of BCL-2 in regulating oxidative
state and mitochondrial metabolism (Chen and Pervaiz, 2007).
Thus, elevated BCL-2 could contribute to key functional proper-
ties of LSCs.
BCL-2 Inhibition Targets LSC Mitochondrial Energy
Generation
To investigate the role of BCL-2 in the metabolic homeostasis
of primitive leukemia cells, we determined the bioenergetic prop-
erties of primary AML cells treated with BCL-2 pharmacologic
inhibitors. We found that within minutes of treatment, the
BCL-2 inhibitor ABT-263 induces severe impairment of OXPHOSell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc. 333
Figure 3. BCL-2 Is Upregulated in LSC-Enriched Primary AML
Populations
(A) Heat map of relative expression of energy and mitochondrial-related genes
in ROS-low AML cells compared to ROS-high cells (green = downregulated,
red = upregulated). RNA was isolated from each purified population from n = 3
independent AML specimens and subjected to whole transcriptome analysis
(RNA-seq) as described in the Experimental Procedures. The two-sample
homoscedastic, independent t test was used for comparing the states
described. p% 0.05 was set as significant. See also Figures S3A and S3B.
(B) Normalized BCL-2 gene expression determined by quantitative real-time
PCR in ROS-high as compared to ROS-low AML subsets. Mean ± SEM values
of n = 7 primary AML specimens are presented (*p% 0.05).
(C) Western blot analyses of BCL-2 protein levels in ROS-low versus ROS-high
leukemia cells. See also Figures S3C–S3H.
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Similarly, a second chemically distinct BCL-2 inhibitor, obato-
clax, also inhibited oxidative respiration in leukemia cells (Fig-
ure S4B), albeit to a lesser extent than ABT-263. This effect is
accompanied by a robust glycolytic response (Figure 4D), indi-
cating that glycolysis is a compensatory mechanism activated
upon inhibition of OXPHOS by BCL-2 inhibitors. ABT-263
similarly impaired OXPHOS in the LSC-enriched ROS-low cells
(Figure 4B). However, in agreement with our previous findings334 Cell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc.showing that ROS-low AML cells have reduced reserved glyco-
lytic capacity (Figures 2D and 2E), ROS-low cells were not able to
induce glycolysis (Figure 4D). These findings suggested that
ABT-263 should selectively inhibit energy generation in the
ROS-low population. Indeed, ABT-263 rapidly depleted cellular
ATP in the ROS-low AML subset (Figure 4E, left panel), whereas
it had no effect in the ATP content of the ROS-high population
(Figure 4E, middle panel).
To investigate the role of BCL-2 in normal populations, we
tested the effect of ABT-263 treatment in CD34+ cells from
healthy donors. As shown in Figure 4C, OCRwas impaired, albeit
to a lesser extent than that observed in leukemic cells. In agree-
ment with our data showing that normal CD34+ cells possess
reserve glycolytic capacity (Figure 2H), we detected a clear up-
regulation of glycolysis in normal CD34+ subsets in response
to ABT-263-induced OXPHOS inhibition (Figure 4D). Impor-
tantly, evaluation of the effect of ABT-263 on the ATP content
of normal CD34+ progenitors revealed no significant impact,
unless ABT-263was combinedwith the glycolysis inhibitor 2-de-
oxyglucose (2-DG) (Figure 4E, right panel). The combination of
ABT-263 and 2-DG induced a decrease in the ATP content of
normal CD34+ cells to levels similar to those observed in ROS-
low AML cells treated with ABT-263 alone. These data indicate
that glycolytic capacity represents an important biological prop-
erty that distinguishes ROS-low AML cells from normal CD34+
cells.
To more directly address the role of BCL-2 in the oxidative
respiration of leukemia cells, we employed an shRNA strategy
to genetically reduce gene expression. Using lentiviral-mediated
gene transfer, we expressedBCL-2 shRNAs in primary AML cells
and the U937 leukemia cell line (Figure S4C). Primary leukemic
and U937 cells transduced with BCL-2 shRNA showed a sig-
nificantly reduced basal oxygen consumption rate as com-
pared to cells transduced with a control vector (Figure 4F and
Figure S4D), indicating that BCL-2 is a positive regulator of
OXPHOS in leukemia cells. Further, the capacity of ABT-263
to suppress oxidative respiration was markedly decreased in
BCL-2 shRNA-transduced primary AML cells as compared to
vector control cells (Figure 4G and Figure S4E). Knocking
down BCL-XL (the other known target of ABT-263) (van Delft
et al., 2006) by specific shRNA did not have a significant effect
on the OXPHOS of primary leukemic cells (Figure S4F). Taken
together, these findings strongly indicate that inhibition of oxida-
tive respiration induced by treatment with ABT-263 is mediated
by inhibition of BCL-2.
BCL-2 Inhibition Induces Cell Death in the LSC
Compartment
Based on our finding that BCL-2 inhibition inducedmitochondrial
dysfunction and energy depletion in ROS-low cells, we next
asked if oxidation was promoted. To this end, we measured
mitochondrial ROS levels using the mitochondrial superoxide
detector MitoSox-Red. We found that ABT-263 induces a clear
upregulation of mitochondrial ROS selectively in LSC-enriched
ROS-low cells (Figure 5A and Figure S5). As BCL-2 inhibition
increased the oxidative state of ROS-low cells, we investigated
whether changes in antioxidant defenses were evident. We
found that ABT-263 treatment resulted in decreased levels of
reduced glutathione (GSH) in the ROS-low subset (Figure 5C).
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Figure 4. BCL-2 Inhibitors Target LSCMito-
chondrial Energy Generation
(A and B) Plots of oxygen consumption rate (OCR,
oxidative metabolism) as a parameter of time in
the absence (measurements 1–4) and presence
(measurements 4–12) of 250nM ABT-263 (indi-
cated by black arrow) in total AML and ROS-high
primary AML subsets (A) and in LSC-enriched
ROS-low cells (B). Five replicate wells of 1 3 106
total AML, ROS-low, and ROS-high leukemic cells
were analyzed. Consecutive measurements (1–12)
in both plots were performed every 15 min.
(C) CD34+ cells isolated from normal bone marrow
were analyzed similarly to those in (A). See also
Figures S4A and S4B.
(D) Extracellular acidification rate (ECAR, glyco-
lytic rate) is plotted as a parameter of time in
total AML, ROS-low, and ROS-high subsets, and
in normal marrow CD34+ cells in the absence
(measurements 1–4) and presence (measure-
ments >4) of 250nM ABT-263.
(E) ATP levels in ROS-low versus ROS-high AML
subsets with or without ABT-263 (250nM, 6 hr),
and in normal marrow CD34+ cells treated either
with ABT-263 alone (250nM, 6 hr) or ABT-263
(250nM) and 2-deoxyglucose (2-DG, 5mM) for
6 hr. Normalized mean values of treated cells as
compared to untreated controls (presented as
equal to 1) are plotted. *p% 0.05.
(F) Two independent primary AML specimens
were transduced with shRNA targeting BCL-2 by
means of lentiviral vectors, as described in the
Experimental Procedures. BCL-2 knockdown was
confirmed by quantitative RT-PCR (Figure S4C).
Baseline OCR indicative of oxidative respiration
was analyzed in cells transduced with BCL-2
shRNA and empty vector, and is plotted. Mean ±
SEM of two independent experiments are shown.
*p% 0.05.
(G) Primary AML cells transduced with BCL-2
shRNA versus empty vector were treated with
ABT-263 (1 mM). OCR values 60 min after treat-
ment are plotted as normalized percentage values
of baseline (no drug) values for each sample.
Mean ± SEM of two independent experiments are
shown. *p% 0.05. See also Figures S4D–S4F.
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Energy Metabolism in Leukemia Stem CellsKinetic studies determined that mitochondrial oxidation and
glutathione depletion are detectable after 4–6 hr of in vitro expo-
sure of ROS-low cells to BCL-2 pharmacologic inhibitors, and
these events occur subsequent to the effects of BCL-2 inhibitors
on OXPHOS and the cellular ATP content (not shown). Taken
together, our redox and bioenergetic studies showed that
BCL-2 inhibition severely impaired LSC redox and energy
control. To investigate BCL-2 inhibition as a means for eradi-
cating primitive AML cells, we evaluated the in vitro sensitivity
of ROS-low AML to BCL-2 inhibitors. We first used ABT-737,
which is a closely related analog of ABT-263 with similar struc-Cell Stem Cell 12, 329–3tural features, but which, in contrast to
ABT-263, is not orally bioavailable. Those
studies showed a dramatic targeting of
ROS-low cells with much less effect in
the ROS-high compartment (Figure 5B).Additional studies with ABT-263 show consistently strong
toxicity to the LSC-enriched ROS-low population with generally
less activity toward ROS-high cells, indicating a selective role of
BCL-2 in LSC survival (Figure 5D).
To evaluate the relative contribution of ABT-263-induced
oxidation in LSC cell death, we investigated whether ROS-low
cells would be rescued from BCL-2 inhibitor toxicity by the
antioxidants NAC and GSH-ester. NAC and the GSH-ester
did not significantly reduce ABT-263 toxicity in ROS-low cells
(Figure 5E), indicating the effects of ABT-263 on LSC oxidative
state as a late component of the LSC cell death process rather41, March 7, 2013 ª2013 Elsevier Inc. 335
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Figure 5. BCL-2 Inhibitors Induce Mitochondrial Oxidation and Cell Death in the LSC Compartment
(A) Mitochondrial ROS, as evaluated by themitochondrial-specific redox probeMitoSox in ROS-low versus ROS-high AML subsets treated with 250nM ABT-263
for 6 hr. Gray filled, untreated; red line, +ABT-263. See also Figure S5.
(B) Flow cytometric cell death analysis of ROS-low and ROS-high leukemia cells in an AML specimen treated for 18 hr with increasing concentrations of the BCL-2
inhibitor ABT-737. Treated and control cells were labeled with Annexin V and 7AAD and analyzed by flow cytometry. The number of viable (Ann/7AAD) cells is
shown.
(C) Reduced GSH levels in primary ROS-low cells subjected to 250nM ABT-263 for 6 hr. Normalized mean values of treated cells as compared to untreated
controls (presented as equal to 1) are plotted in n = 4 AML specimens. *p% 0.05.
(D) In vitro cell death analyses of ROS-low versus ROS-high AML populations in n = 6 AML specimens are shown. Results are expressed as the ratio of the mean
viable (Ann/7AAD) treated cells to the mean viable cells of untreated controls. Red, ROS-low; black, ROS-high.
(E) In vitro viability of ROS-low cells treated for 18 hr with 250nMABT-263 alone, or ABT-263 in combination with 1mMNAC or 1mMGSH-ester. Mean values from
duplicate experiments in three independent AML specimens are plotted. *p% 0.05.
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Energy Metabolism in Leukemia Stem Cellsthan initiators of cell death. The AML ROS-low cell oxida-
tion following OXPHOS inhibition and cell death induction in
response to ABT-263 is not comparable to our findings in
steady state conditions, where lower overall and mitochondrial
ROS associated with a relatively lower OCR rate (Figure 2A
and Figure S2). Further, although ROS-low cells treated with336 Cell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc.ABT-263 became oxidized, they remained in a quiescent
state (Table S4), excluding the possibility of an increase in
LSC cell cycle activity as a mechanism of cell death in response
to BCL-2 inhibition. Taken together, our findings suggest that
BCL-2 inhibitors target LSCs by selectively impairing LSC
energy homeostasis.
Cell Stem Cell
Energy Metabolism in Leukemia Stem CellsBCL-2 Inhibition Therapeutically Targets Functionally
Defined LSCs
To further investigate BCL-2 inhibition as an approach to target
primitive AML cells, we first examined the colony forming poten-
tial of primary AML cells transduced with BCL-2 shRNA versus
that of control cells. As shown in Figure 6A, BCL-2 knockdown
dramatically reduced the colony forming capacity of primary
leukemic blasts. Next, we performed xenograft analyses. We
treated LSC-enriched ROS-low AML populations in vitro with
concentrations of the BCL-2 inhibitor ABT-263 equal to the
IC50 concentration of the total AML cells for each sample, and
then transplanted treated or vehicle control cells into NSG
mice. As shown in Figure 6B, ABT-263 reduced LSC potential
in all AML specimens evaluated by this functional assay. Impor-
tantly, parallel studies performed with the standard chemo-
therapy agent daunorubicin (DNR), showed almost no activity
toward ROS-low LSC engraftment (Figure S6). Next, we also
tested the antileukemic effect of pharmacologic BCL-2 inhibitors
in vivo by treating mice engrafted with primary human AML cells
with ABT-737 (50 mg/kg IP for 15 days). As shown in Figure 6C,
ABT-737 clearly reduced leukemia burden in the treated mice.
Human leukemic cells isolated frommice that received treatment
with ABT-737 were transplanted into secondary recipient mice
and demonstrated reduced engraftment compared to leukemic
cells from control mice (mean ± SEM: 43.2 ± 5.7 versus 89.2 ±
2.5, p < 0.05) (Figure 6D). These findings indicate that in addition
to reducing the bulk tumor, ABT-737 targets the LSC compart-
ment. As previously shown (Konopleva et al., 2006), we also
found that ABT-263 did not impact the in vitro survival of normal
bone marrow CD34+ cells, or the clonogenic potential of normal
marrow progenitors (Figures 6E and 6F). Further, functional anal-
ysis of total bone marrow mononuclear cells treated overnight
in vitro with 250nM ABT-263 and then transplanted in NSG
mice showed no significant effect of ABT-263 on the engraftment
potential of normal HSCs (Figure 6G). Taken together, these
results indicate that BCL-2 inhibition may be an effective means
of targeting quiescent ROS-low LSCs.
DISCUSSION
Developing effective strategies to target human LSCs has
proven to be a challenging task. While a number of strategies
have been proposed based on studies in preclinical models,
the clinical utility of such methods remains unclear. An added
difficulty that has come to light in recent years is the likely
complexity and heterogeneity of the LSC population (Sarry
et al., 2011). Evidence from human leukemia studies, as well
as related efforts in other cancers, have suggested that the prop-
erties defining ‘‘stemness’’ may vary among individual AML
patients, as well as within the same patients during the course
of disease pathogenesis (Eppert et al., 2011; Sarry et al.,
2011). Consequently, it has become increasingly important
to determine whether any biological properties are relatively
consistent in LSC populations, irrespective of disease stage or
the nuances of any individual tumor population. Indeed, funda-
mental LSC-specific characteristics remain a highly desirable
focal point for the development of improved therapies.
In the present study, we examined the properties of LSCs with
respect to oxidative status and energy production. In agreementCwith previous reports on normal stem cells and breast CSCs
(Diehn et al., 2009; Jang and Sharkis, 2007; Smith et al., 2000),
we observe substantial heterogeneity in LSC oxidative state,
an underlying measure of energy metabolism. However, we
show that similar to normal stem cell populations (Jang and
Sharkis, 2007; Smith et al., 2000), functionally defined LSCs
preferentially reside in a reduced state (ROS-low). Our findings
in LSC-enriched populations, and previous studies in breast
CSCs, indicate a low oxidative state as a potentially frequent
CSC property (Diehn et al., 2009). Further, we show here that
LSC-enriched populations are characterized by quiescent cell
cycle status and low energy production. This relatively dormant
condition likely enables LSCs to persist, even under restrictive
conditions such as low nutrient or oxygen levels. Intriguingly
though, in contrast to our findings in normal CD34+ and previous
findings in murine HSCs, both showing that normal stem cells
efficiently utilize glycolysis for energy homeostasis (Simsek
et al., 2010), ROS-low LSCs appear to be deficient in their ability
to employ glycolysis, and are highly reliant on OXPHOS. Glioma
stem cells were also shown to be more reliant on oxidative respi-
ration for energy generation, suggesting that lack of glycolytic
activity in stem cells may be a broader characteristic of cancers
(Vlashi et al., 2011). If true, then therapeutic strategies based on
the assumption that tumors are preferentially reliant on glycol-
ysis may need to be reconsidered.
Why ROS-low self-renewing LSC populations, in contrast to
the bulk tumor and normal HSCs (Simsek et al., 2010), are less
efficient in employing glycolysis represents an important avenue
of future investigation. We consider it unlikely that the LSCmeta-
bolic profile identified in our study is an artifact of ex vivo cell
manipulation, since if this were the case we would expect all
leukemic cells to exhibit this phenotype, instead of just the
ROS-low subset. Intriguingly, it has been recently proposed
that cancer cell subsets with different dependencies in energy-
generating pathways coexist within tumors in a symbiotic
manner (Nakajima and Van Houten, 2012). In particular, cancer
populations that depend on glycolysis for energy generation
secrete lactate as a byproduct that is subsequently imported
and used as a fuel for oxidative respiration by cancer subsets
dependent on oxygen metabolism. Evaluating if this symbiotic
model has relevance to the CSC model represents an intriguing
line of future investigation. Further, it is possible that the para-
doxical OXPHOS dependence of the ROS-low LSC-enriched
subset is part of a wider metabolic adaptation of these cells,
as they successfully maintain survival despite a dramatically
reduced overall metabolic rate. Since oxidative respiration is
a slower but significantly more efficient mechanism of energy
generation, quiescent LSC subsets may benefit in the long
term by using OXPHOS in the context of the tumor microenviron-
ment, as they can more efficiently utilize the limited available
nutrients.
By performing gene expression analyses and molecular
studies, we show that BCL-2 is preferentially elevated in LSC-en-
riched ROS-low cells. Although BCL-2 is commonly upregulated
in cancer, a differential role for BCL-2 in cancer stem cells has
not beenwidely considered. Notably though, one study by Kono-
pleva et al. (2006) previously demonstrated the activity of BCL-2
inhibitor ABT-737 toward leukemia cells types, including primary
AML CD34+/CD38 cells. These initial studies first establishedell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc. 337
Figure 6. BCL-2 Inhibition Targets Drug-Resistant LSCs
(A) Colony-forming potential of primary AML cells transduced with BCL-2 shRNAs or empty vector. Mean ± SEM values of two independent experiments in
triplicate are shown.
(B) Ex vivo cell death analysis of LSC-enriched ROS-low cells treated with ABT-263 in three independent AML specimens. Cells were cultured overnight in vitro
with ABT-263 concentrations equal to the IC50 drug dose for total AML cells, and then injected into NSG mice. The percentage engraftment of human cells is
plotted. *p% 0.05; ns, not significant. See also Figure S6.
(C) Percentage engraftment of human leukemia cells in NSG mice treated in vivo with vehicle (control) or ABT-737 (50 mg/kg, IP for 14 daily doses).
(D) Human engrafted cells from mice treated in vivo with ABT-737 and respective cells from mice treated with vehicle (control) from the experiment shown
in (C) were isolated, and equal numbers of cells were transplanted in secondary recipients. Mice were analyzed for engraftment of human leukemic cells
8 weeks after.
(E) In vitro cell death analysis of normal bonemarrow cells treated with ABT-263 (250nM, 18 hr), after gating in the CD34+ hematopoietic progenitor compartment.
(F) Normal bone marrow cells were treated in vitro with ABT-263 (250nM, 18 hr) followed by methylcellulose culture to measure colony formation ability. Mean ±
SEM values of two independent experiments in triplicate are shown. ns, not significant.
(G) Ex vivo cell death analysis of normal bonemarrow total mononuclear cells cultured overnight in vitro with 250nMABT-263 and subsequently injected into NSG
mice. The percentage engraftment of human cells is plotted.
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Figure 7. Model for Selective Targeting of LSCs by BCL-2 Inhibition
Upper panel: AML ROS-low cells under baseline conditions are characterized,
as compared to AML ROS-high cells, by quiescence, low overall intracellular
ROS, low metabolism that generates energy through oxidative respiration
rather than glycolysis, and transcriptional upregulation of BCL-2. BCL-2
positively regulates energy generation in AMLROS-low and ROS-high subsets
through upregulating oxidative respiration. AML ROS-high cells employ
additional mechanisms to maintain a significantly higher metabolic/energetic
state as compared to AML ROS-low.
Lower panel: Based on the increased expression of BCL-2 in AML ROS-low
cells, and their selective dependency on oxidative respiration for energy
homeostasis, upon BCL-2 pharmacologic inhibition by treatment with ABT-
263, the OXPHOS of AML ROS-low cells is dramatically reduced, those cells
cannot increase glycolysis so as to maintain energy supply, and ATP levels are
depleted. This is followed by an increase in mitochondrial ROS, a reduction in
cellular glutathione, and the induction of apoptotic cell death. AML ROS-high
cells can more efficiently preserve energy supplies in response to BCL-2
pharmacologic inhibition, mainly by upregulating the glycolytic machinery.
Cell Stem Cell
Energy Metabolism in Leukemia Stem Cellsthe concept of using BCL-2 inhibition as a strategy for targeting
primitive leukemia cells. Our studies extend the work by Kono-
pleva et al. and provide novel insights on the role of BCL-2 in
promoting LSC metabolic homeostasis. Further, by employing
xenograft analyses we demonstrate here that both ABT-737
and its optimized orally bioavailable analog, ABT-263, not only
decrease bulk leukemia burden, but also target functionally
defined LSCs.
From a mechanistic standpoint the high levels of BCL-2
expression we observe in ROS-low cells may promote LSC
survival in response to stressful stimuli such as chemotherapy
and irradiation by inhibiting the mitochondrial proapoptotic
pathway (Del Poeta et al., 2003). In addition, we demonstrate
that BCL-2 mediates oxidative respiration, which our findings
indicate as essential for LSC energy homeostasis (Figure 7).
The role of BCL-2 in promoting mitochondrial bioenergetics
offers a unique opportunity for drug targeting in the LSC-specific
context, as LSCs not only express high levels of BCL-2 but also
have a selective dependency on oxidative respiration. In this
vein, we demonstrate that the BCL-2 inhibitors ABT-737 and
ABT-263 inhibit LSC oxidative respiration, which is accompa-
nied by selective eradication of ROS-low cells. Importantly, we
and others have shown that this class of drugs does not affect
normal HSCs (Konopleva et al., 2006). The identification of
BCL-2 inhibitors as LSC targeting agents, together with the
absence of significant toxicity to normal cells, is intriguing, since
it provides a basis for clinical investigation of those drugs at
disease stages where targeting residual LSCs is essential, as
for instance in consolidation therapy or maintenance treatment
during remission.
In conclusion, the concept of targeting cancer cell metabolism
has emerged as an intriguing approach to the development
of improved therapeutic regimens. We demonstrate here that it
is feasible to eradicate resistant LSC populations by targeting
their unique metabolic dependencies. Understanding further
the metabolic regulation of leukemia stem cells may yield
improved therapeutic strategies to eradicate this highly drug-
resistant tumor population.
EXPERIMENTAL PROCEDURES
Primary AML and Normal Hematopoietic Cells
Normal and leukemic human bone marrow samples were obtained after
informed consent from volunteer donors at the University of Rochester
Medical Center. Patient clinical characteristics are detailed in Table S1 Total
bone marrow mononuclear cells were isolated by standard Ficoll procedures
(GE Healthcare, Piscataway, NJ) and cryopreserved in freezing medium con-
sisting of Cryostor CS10 (BioLife Solutions). The viability of leukemic cells after
thawing was 50%–90%. Normal bone marrow total mononuclear cells were
further enriched for CD34+ cells using MACS CD34 enrichment kit (Milltenyi
Biotec, Auburn, CA).
Measurement of Endogenous ROS and Cell Separation Based on
ROS Levels
Endogenous ROS levels of primary AML specimens were detected by labeling
13 106 leukemic cells for 15 min at 37Cwith the redox-sensitive probes CM-
H2DCFDA (5mM), CellRox (5mM), MitoSox (5mM), Dihydroethidium (2mM),
or Mitotracker (1mM)(Life Technologies). Labeled cells were resuspended in
0.2 ml of 10uM DAPI (Invitrogen) solution and analyzed using BD LSRII flow
cytometer (BD Biosciences) and FlowJo software (Treestar).
For cell separation based on endogenous ROS levels, 1 3 108 cells were
stained with 10mMCM-H2DCFDA or 8mMCellRox for 15 min at 37C, washedCwith PBSwith 0.5%FBS, and resuspended in 10uMDAPI solution. Viable AML
cells containing lower ROS (bottom 15%of dye distribution) or higher ROS (top
15% of dye distribution) were collected after gating in the DAPI population by
a BD ARIAII cell sorter (San Jose, CA).
Animal Studies
Sublethally irradiated NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jack-
son Laboratories, Bar Harbor, ME) were injected with human leukemic cells
via tail vein in a final volume of 0.2 ml of PBS with 0.5% FBS. Total AML: sortedell Stem Cell 12, 329–341, March 7, 2013 ª2013 Elsevier Inc. 339
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5:1:1. Based on the isolation of ROS-low (and respective ROS-high) AML
subset as15% of the bulk AML cells, this adjustment of the injected cell ratio
enables transplantation of approximately equal absolute numbers of ROS-low
cells in mice injected with total leukemia cells and in mice injected with purified
ROS-low, so as to provide a relative estimate of the contribution of the AML
ROS-low cells to the engraftment of the total AML cells.
For secondary transplantation studies of AML specimens, engrafted human
cells from mice injected with total, ROS-low, and ROS-high AML cells were
adjusted to equal numbers and injected to irradiated NSG secondary recipi-
ents. In primary and secondary transplantation experiments, animals were
killed after 6–8 weeks and bone marrow was analyzed, by flow cytometry,
for the presence of human CD45 and human CD33 to indicate human cells.
Metabolic Assays
O2 consumption and lactate generation were measured using the Seahorse
XF24 extracellular flux analyzer as previously described (Varum et al., 2011).
Briefly, five replicate wells of 5 3 105 leukemic or normal cells per well were
seeded overnight in 24-well XF24 well plates coated with BD Cell-Tak (BD
Biosciences) in serum-free culture medium. One hour prior to analysis, the
medium was replaced by unbuffered DMEM and the well plates were incu-
bated to 37C for pH stabilization. Analyses were performed both at basal
conditions and after injection of OLI (1 mg/ml), FCCP (1 mM), Antimycin A
(5 mM), ABT-263 (250nM-1 mM), and obatoclax (10 mM). ATP levels were deter-
mined according to manufacturer instructions by the ATP Bioluminescence
Assay Kit HS II (Roche). The protein expression of the NOX2 (gp91phox)
subunit of the NADPH oxidase was detected by flow cytometry after cells
were labeled with anti-NOX2 antibody (bs-3889R, Bios USA) as previously
described (Hole et al., 2010).
In Vivo Treatment of Xenografts with ABT-737
Irradiated NSG mice were transplanted with human leukemia cells (3 3 106/
mouse) via tail vein in a final volume of 0.2 ml of PBS with 0.5% FBS. After
2 weeks, animals were size-matched to treatment and control groups
(10 animals per group) and received either ABT-737 (50 mg/kg, IP for 14 daily
doses) or vehicle. ABT-737 was formulated in 30% propylene glycol, 5%
Tween 80, and 65% dextrose and prepared freshly every day. After treatment,
mice were sacrificed and human engrafted cells were evaluated by flow
cytometry.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes six figures, four tables, and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2012.12.013.
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